{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:38:51Z","timestamp":1793126331578,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8053-00051B"],"award-info":[{"award-number":["8053-00051B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Animal models of non-alcoholic steatohepatitis (NASH) are important tools in preclinical research and drug discovery. Gubra-Amylin NASH (GAN) diet-induced obese (DIO) mice represent a model of fibrosing NASH. The present study directly assessed the clinical translatability of the model by head-to-head comparison of liver biopsy histological and transcriptome changes in GAN DIO-NASH mouse and human NASH patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>C57Bl\/6\u2009J mice were fed chow or the GAN diet rich in saturated fat (40%), fructose (22%) and cholesterol (2%) for \u226538\u2009weeks. Metabolic parameters as well as plasma and liver biomarkers were assessed. Liver biopsy histology and transcriptome signatures were compared to samples from human lean individuals and patients diagnosed with NASH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Liver lesions in GAN DIO-NASH mice showed similar morphological characteristics compared to the NASH patient validation set, including macrosteatosis, lobular inflammation, hepatocyte ballooning degeneration and periportal\/perisinusoidal fibrosis. Histomorphometric analysis indicated comparable increases in markers of hepatic lipid accumulation, inflammation and collagen deposition in GAN DIO-NASH mice and NASH patient samples. Liver biopsies from GAN DIO-NASH mice and NASH patients showed comparable dynamics in several gene expression pathways involved in NASH pathogenesis. Consistent with the clinical features of NASH, GAN DIO-NASH mice demonstrated key components of the metabolic syndrome, including obesity and impaired glucose tolerance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The GAN DIO-NASH mouse model demonstrates good clinical translatability with respect to the histopathological, transcriptional and metabolic aspects of the human disease, highlighting the suitability of the GAN DIO-NASH mouse model for identifying therapeutic targets and characterizing novel drug therapies for NASH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-020-01356-2","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T10:02:58Z","timestamp":1594029778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3732-0281","authenticated-orcid":false,"given":"Henrik H.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene M.","family":"\u00c6gidius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Or\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Heeb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Lykke","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Louise","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne S.","family":"Veidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte P.","family":"Suppli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Trevaskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Jelsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer T. G.","family":"Rigbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"1356_CR1","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","volume":"65","author":"GT Brown","year":"2016","unstructured":"Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism. 2016;65:1080\u20136.","journal-title":"Metabolism."},{"key":"1356_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801.","journal-title":"J Hepatol"},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","volume":"113","author":"M Noureddin","year":"2018","unstructured":"Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113:1649\u201359.","journal-title":"Am J Gastroenterol"},{"key":"1356_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348.","journal-title":"Metabolism."},{"key":"1356_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-3-030-11748-1_14","volume-title":"Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease","author":"H Hansen","year":"2019","unstructured":"Hansen H, Hansen G, Secher T, Feigh M, Veidal S, Fosgerau K, et al. Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis \u2013 clinical translatability and applicability in preclinical drug development. In: Krentz A, Weyer C, Hompesch M, editors. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2nd ed. Cham: Springer; 2019. p. 369\u2013403.","edition":"2"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/jgh.14122","volume":"33","author":"F Haczeyni","year":"2018","unstructured":"Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, et al. Mouse models of non-alcoholic steatohepatitis: a reflection on recent literature. J Gastroenterol Hepatol (Australia). 2018;33:1312\u201320.","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"1356_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen HH, Feigh M, Veidal SS, Rigbolt KTG, Vrang N, Fosgerau K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707\u201318.","journal-title":"Drug Discov Today"},{"key":"1356_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","volume":"7","author":"JS Lim","year":"2010","unstructured":"Lim JS, Mietus-Snyder M, Valente A, Schwarz J-M, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1356_CR9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1586\/17474124.2015.1092382","volume":"9","author":"SM Walenbergh","year":"2015","unstructured":"Walenbergh SM, Shiri-Sverdlov R. Cholesterol is a significant risk factor for non-alcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2015;9:1343\u20136.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1356_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/egh.09.32","volume":"3","author":"N Alkhouri","year":"2009","unstructured":"Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009;3:445\u201351.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"G987","DOI":"10.1152\/ajpgi.90272.2008","volume":"295","author":"LH Tetri","year":"2008","unstructured":"Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. AJP Gastrointest Liver Physiol. 2008;295:G987\u201395.","journal-title":"AJP Gastrointest Liver Physiol."},{"key":"1356_CR12","doi-asserted-by":"publisher","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","volume":"305","author":"JR Clapper","year":"2013","unstructured":"Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. AJP Gastrointest Liver Physiol. 2013;305:G483\u201395.","journal-title":"AJP Gastrointest Liver Physiol"},{"key":"1356_CR13","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. AJP Gastrointest Liver Physiol. 2012;302:G762\u201372.","journal-title":"AJP Gastrointest Liver Physiol."},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:179\u201394.","journal-title":"World J Gastroenterol"},{"key":"1356_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","volume":"24","author":"JD Roth","year":"2018","unstructured":"Roth JD, Feigh M, Veidal SS, Fensholdt LKD, Rigbolt KT, Hansen HH, et al. INT-767 improves histopathological features in a diet-induced Ob\/Ob mouse model of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24:195\u2013210.","journal-title":"World J Gastroenterol"},{"key":"1356_CR16","doi-asserted-by":"publisher","first-page":"9046","DOI":"10.1038\/s41598-019-45178-z","volume":"9","author":"JD Roth","year":"2019","unstructured":"Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, et al. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced Ob\/Ob mouse model of biopsy-confirmed NASH. Sci Rep. 2019;9:9046.","journal-title":"Sci Rep"},{"key":"1356_CR17","doi-asserted-by":"crossref","unstructured":"Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, et al. Progression and regression of hepatic lesions in a mouse model of NASH induced by dietary intervention and its implications in pharmacotherapy. Front Pharmacol. 2018;9:410.","DOI":"10.3389\/fphar.2018.00410"},{"key":"1356_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146337","volume":"11","author":"Y Honda","year":"2016","unstructured":"Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic Steatohepatitis in mice. PLoS One. 2016;11:e0146337.","journal-title":"PLoS One"},{"key":"1356_CR19","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","volume":"6","author":"H Jouihan","year":"2017","unstructured":"Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, et al. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360\u201370.","journal-title":"Mol Metab"},{"key":"1356_CR20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/hep4.1368","volume":"3","author":"ED Hernandez","year":"2019","unstructured":"Hernandez ED, Zheng L, Kim Y, Fang B, Liu B, Valdez RA, et al. Tropifexor-mediated abrogation of Steatohepatitis and fibrosis is associated with the Antioxidative gene expression profile in rodents. Hepatol Commun. 2019;3:1085\u201397.","journal-title":"Hepatol Commun"},{"key":"1356_CR21","unstructured":"US Food & Drug Administration. Final Determination Regarding Partially Hydrogenated Oils (Removing Trans Fat). https:\/\/www.fda.gov\/food\/ingredientspackaginglabeling\/foodadditivesingredients\/ucm449162.htm. Accessed 18 May 2018."},{"key":"1356_CR22","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","volume":"25","author":"ML Boland","year":"2019","unstructured":"Boland ML, Or\u00f3 D, T\u00f8lb\u00f8l KS, Thrane ST, Nielsen JC, Cohen TS, et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source. World J Gastroenterol. 2019;25:4904\u201320.","journal-title":"World J Gastroenterol"},{"key":"1356_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","volume":"51","author":"S Heeb\u00f8ll","year":"2016","unstructured":"Heeb\u00f8ll S, Kreuzfeldt M, Hamilton-Dutoit S, Kj\u00e6r Poulsen M, St\u00f8dkilde-J\u00f8rgensen H, M\u00f8ller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456\u201364.","journal-title":"Scand J Gastroenterol"},{"key":"1356_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.clinre.2019.01.001","volume":"43","author":"P Lykke Eriksen","year":"2019","unstructured":"Lykke Eriksen P, S\u00f8rensen M, Gr\u00f8nb\u00e6k H, Hamilton-Dutoit S, Vilstrup H, Thomsen KL. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. Clin Res Hepatol Gastroenterol. 2019;43:551\u201360.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1356_CR25","first-page":"G462","volume":"316","author":"MP Suppli","year":"2019","unstructured":"Suppli MP, Rigbolt KTG, Veidal SS, Heeb\u00f8ll S, Eriksen PL, Demant M, et al. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. Am J Physiol Liver Physiol. 2019;316:G462\u201372.","journal-title":"Am J Physiol Liver Physiol"},{"key":"1356_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia."},{"key":"1356_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology."},{"key":"1356_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","volume":"8","author":"MNB Kristiansen","year":"2016","unstructured":"Kristiansen MNB, Veidal SS, Rigbolt KTG, T\u00f8lb\u00f8l KS, Roth JD, Jelsing J, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol. 2016;8:673.","journal-title":"World J Hepatol"},{"key":"1356_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12876-019-1149-z","volume":"19","author":"MN Baandrup Kristiansen","year":"2019","unstructured":"Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, et al. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterol. 2019;19:228.","journal-title":"BMC Gastroenterol"},{"key":"1356_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"1356_CR31","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1356_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/liv.14354","volume":"40","author":"A Cardoso","year":"2020","unstructured":"Cardoso A, Figueiredo-Mendes C. A. Villela-Nogueira C, Sanyal AJ. New drugs for non-alcoholic steatohepatitis. Liver Int. 2020;40:96\u2013101.","journal-title":"Liver Int"},{"key":"1356_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/en.2012-1937","volume":"154","author":"N Panjwani","year":"2013","unstructured":"Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE ?\/? Mice. Endocrinology. 2013;154:127\u201339.","journal-title":"Endocrinology"},{"key":"1356_CR34","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1210\/me.2010-0142","volume":"24","author":"K Fon Tacer","year":"2010","unstructured":"Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010;24:2050\u201364.","journal-title":"Mol Endocrinol"},{"key":"1356_CR35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0167-4781(98)00255-3","volume":"1444","author":"T Nishimura","year":"1999","unstructured":"Nishimura T, Utsunomiya Y, Hoshikawa M, Ohuchi H, Itoh N. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta - Gene Struct Expr. 1999;1444:148\u201351.","journal-title":"Biochim Biophys Acta - Gene Struct Expr"},{"key":"1356_CR36","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1074\/jbc.M209706200","volume":"278","author":"Y Kawamata","year":"2003","unstructured":"Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435\u201340.","journal-title":"J Biol Chem"},{"key":"1356_CR37","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0002-9440(10)65477-6","volume":"155","author":"P Bono","year":"1999","unstructured":"Bono P, Jalkanen S, Salmi M. Mouse vascular adhesion protein 1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis. Am J Pathol. 1999;155:1613\u201324.","journal-title":"Am J Pathol"},{"key":"1356_CR38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cpt.1301","volume":"105","author":"M Drozdzik","year":"2019","unstructured":"Drozdzik M, Busch D, Lapczuk J, M\u00fcller J, Ostrowski M, Kurzawski M, et al. Protein abundance of clinically relevant drug transporters in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2019;105:1204\u201312.","journal-title":"Clin Pharmacol Ther"},{"key":"1356_CR39","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1124\/dmd.109.027177","volume":"37","author":"X Cheng","year":"2009","unstructured":"Cheng X, Klaassen CD. Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. Drug Metab Dispos. 2009;37:2178\u201385.","journal-title":"Drug Metab Dispos"},{"key":"1356_CR40","doi-asserted-by":"publisher","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","volume":"9","author":"W Liang","year":"2014","unstructured":"Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014;9:e115922.","journal-title":"PLoS One"},{"key":"1356_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MEG.0000000000001240","volume":"31","author":"Y Yilmaz","year":"2019","unstructured":"Yilmaz Y, Eren F. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol. 2019;31:43\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1356_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.5604\/16652681.1171767","volume":"14","author":"M Kawanaka","year":"2015","unstructured":"Kawanaka M, Nishino K, Nakamura J, Urata N, Oka T, Goto D, et al. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Ann Hepatol. 2015;14:837\u201344.","journal-title":"Ann Hepatol"},{"key":"1356_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW-S Wong","year":"2018","unstructured":"Wong VW-S, Adams LA, de L\u00e9dinghen V, Wong GL-H, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1356_CR44","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","volume":"65","author":"JP Arab","year":"2017","unstructured":"Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65:350\u201362.","journal-title":"Hepatology."},{"key":"1356_CR45","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","volume":"59","author":"R Pais","year":"2013","unstructured":"Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550\u20136.","journal-title":"J Hepatol"},{"key":"1356_CR46","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.30506","volume":"70","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang X-J, Li H. The role of innate immune cells in nonalcoholic Steatohepatitis. Hepatology. 2019;70:1026\u201337.","journal-title":"Hepatology."},{"key":"1356_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17:81\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1356_CR48","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1356_CR49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0140-6736(94)91969-0","volume":"344","author":"S O\u2019Rahilly","year":"1994","unstructured":"O\u2019Rahilly S, Gray H, Hattersley A, Vaag A. Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet. 1994;344:585\u20139.","journal-title":"Lancet."},{"key":"1356_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2017","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1356_CR51","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hep.20920","volume":"42","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987\u20131000.","journal-title":"Hepatology."},{"key":"1356_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/molmed.2016.00203","volume":"23","author":"J Henkel","year":"2017","unstructured":"Henkel J, Coleman CD, Schraplau A, J\u04e7hrens K, Weber D, Castro JP, et al. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol. Mol Med. 2017;23:1.","journal-title":"Mol Med"},{"key":"1356_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084221","volume":"9","author":"K Ma","year":"2014","unstructured":"Ma K, Malhotra P, Soni V, Hedroug O, Annaba F, Dudeja A, et al. Overactivation of intestinal SREBP2 in mice increases serum cholesterol. PLoS One. 2014;9:e84221.","journal-title":"PLoS One"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01356-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-020-01356-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01356-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:19:26Z","timestamp":1650536366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01356-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01356-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"5 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in the approvals by the Research Ethics Committee of the Capital Region of Denmark (H-6-2014-097), the Danish National Committee on Health Research Ethics (20110132; 1\u201310\u201372-140-14), and the Danish Data Protection Agency (no. GEH-2014-049; 1\u201316\u201302-471-14; 1\u201316\u201302-322-15). All participants gave their written informed consent after receiving information about the biopsy procedure both orally and written before inclusion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HHH, HM\u00c6, DO, SE, AB, SSV, MF and KTGR are employed by Gubra; NV and JJ are owners of Gubra; DM and JLT are employed by Gilead Sciences; SH, PLE, KLT, MPS, FKK and HG declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}